Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 8/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23683598 | 1.00 | RORC (0.59) | RORCCYP2D6HPGDATMIDE | |
| SCHEMBL23683613 | 1.00 | RORC (0.59) | RORCCYP2D6HPGDATMIDE | |
| SCHEMBL20139727 | 0.87 | RORC (0.46) | RORCCYP2D6HPGDATMIDE | |
| SCHEMBL20139666 | 0.87 | RORC (0.46) | RORCCYP2D6HPGDATMIDE | |
| SCHEMBL20149049 | 0.81 | RORC (0.56) | RORC | |
| SCHEMBL23683586 | 0.81 | RORC (0.56) | RORC | |
| Hydrochloric Acid SCHEMBL23683617 | 0.80 | RORC (0.55) | RORC | |
| Hydrochloric Acid SCHEMBL23683618 | 0.80 | RORC (0.55) | RORC | |
| SCHEMBL20139695 | 0.78 | RORC (0.60) | RORCCYP2D6IDEUBE2N | |
| SCHEMBL23683609 | 0.77 | RORC (0.60) | RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| US-11078186-B2 | ROR γ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3538522-A1 | ROR GAMMA MODULATORS | Bristol-Myers Squibb Company (US) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089406-A1 | ROR GAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078186-B2 | ROR γ modulators | RORB, RORC, RORA | RORC 2/4885CYP2D6 425/4885HPGD 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.